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TECHNICAL REPORT
COMBINED EFFECT OF THE ESSENTIAL OIL FROM Chenopodium ambrosioides AND
ANTILEISHMANIAL DRUGS ON PROMASTIGOTES OF Leishmania amazonensis
Lianet MONZOTE(1), Ana Margarita MONTALVO(1), Ramón SCULL(2), Migdalia MIRANDA(2) & Juan ABREU(2)
SUMMARY
To date, there are no vaccines against Leishmania, and chemotherapy remains the mainstay for the control of leishmaniasis.
The drugs of choice used for leishmaniasis therapy are significantly toxic, expensive and with a growing frequency of refractory
infections. Because of these limitations, a combination therapy is the better hope. This work demonstrates that the essential oil
from Chenopodium ambrosioides shows a synergic activity after incubation in conjunction with pentamidine against promastigotes
of Leishmania amazonensis. However, an indifferent effect has been found for combinations of meglumine antimoniate or
amphotericin B and the essential oil.
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The leishmaniases are a diverse group of diseases caused by
protozoan parasites of the genus Leishmania15. The diseases affect about
two million people per annum, with approximately 350 million
individuals at risk worldwide. The control of leishmaniasis remains a
problem. The interruption of zoonotic infection is difficult and no
vaccines exist8.
Pentavalent antimonials are still the mainstay of therapy for
leishmaniasis in most of the world. Recommended secondary drugs
include amphotericin B and pentamidine. However, these agents have
some disadvantages: parenteral mode of administration, long duration
of therapy, toxic effects, cost and parasite resistance11,12. On the basis
of these considerations, the study of new drugs for leishmaniases
treatment is strictly necessary.
Natural products are often overlooked in antiprotozoal
chemotherapy. Plants have been used traditionally in the treatment of
leishmaniases, in particular against cutaneous disease8. Our previous
studies have shown that the essential oil from Chenopodium
ambrosioides (Chenopodiaceae) has a promising activity against
promastigotes and intracellular amastigotes of Leishmania amazonensis
and prevent the development of lesion in BALB/c mice with
experimental cutaneous leishmaniasis16.
After increased unresponsiveness to most of the monotherapeutic
regimens, the combination therapy has found new scope in the treatment
of both cutaneous and visceral leishmaniasis7. Additionally, the
combination of antileishmanial drugs could reduce the potential toxic
side effects and prevent drug resistance. For those reasons, it is
important to critically evaluate the role of combination therapy as new
data14. In this study, we studied the utility of combination treatment
between the essential oil and the currently used antileishmanial drugs
on promastigotes of L. amazonensis.
C. ambrosioides was collected in Pharmacy and Foods Institute,
Havana’s University, Cuba, in July 2001. A voucher specimen (No.
4639) is kept at the Experimental Station of Medicinal Plants “Dr.
Juan Tomás Roig”, Cuba. The essential oil was obtained by distillation,
using a Clevenger’s apparatus, of the aerial parts of the plant, as
previously described16. The antileishmanial agents used in the present
work were meglumine antimoniate (Rhône-Poulenc Rorer, Mexico),
amphotericin B (IMEFA, Havana City, Cuba) and pentamidine (Richet
S.A., Buenos Aires, Argentina).
The strain of L. amazonensis (MHOM/77BR/LTB0016) was kindly
provided by the Department of Immunology, Oswaldo Cruz Foundation,
Brazil. The parasites were routinely isolated from mouse lesions and
maintained as promastigotes at 26 ºC in Schneider’s medium (Sigma
Chem. Co., St. Louis, Mo, USA), containing 10% heat-inactivated foetal
bovine serum (Sigma), 200 U penicillin/mL and 200 mg streptomycin/
µL (Sigma).
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The activity against the promastigote form was assessed by the
method described by BODLEY et al.5. Eleven concentrations of each
compound were assayed in quadruplicate. Exponentially growing cells
(105 promastigotes/mL, 199 µL) were distributed in 96-well plates.
The tested compounds were added in 1 µL, and then incubated at
26 ºC. After 72 h of incubation the motility of the promastigotes was
analyzed by direct observation under an inverted microscope and the
minimal inhibitory concentration (MIC), defined as the lowest
concentration of compounds which completely inhibited growth of
promastigotes, was determined. The parasites were incubated for 3h
with p-nitrophenyl phosphate (20 mg/mL) dissolved in sodium acetate
buffer 1M (BDH, Poole, England), pH 5.5, with 1% Triton X-100 at
37 ºC. The absorbance was determined in an EMS Reader MF Version
2.4-0 spectrophotometer, at a wavelength of 405 nm. The 50%
effective concentration (EC50) was obtained from dose-response
curves fit to data by means of the equation for the sigmoidal E
max
model. The motile promastigotes were checked by inverted
microscope to eliminate possible modulation of the essential oil on
L. amazonensis acid phosphatase activity24. A second experiment was
carried out using different combinations of the essential oil and each
antileishmanial agent. MIC concentrations of each compound were
used as the first concentration. The activity (EC50) was measured
with the same protocol. All experiments were carried out in triplicate.
Results were expressed as mean ± standard deviation.
Afterwards, the reduction in the EC50 was calculated of each
compound in the presence of the other. The result is expressed as the
fractional inhibitory concentration (FIC) index, which is assessed as
follows: FIC = [A]/EC50A + [B]/EC50B, where EC50A and EC50B are
the EC50 of each compound alone and [A] and [B] are the EC50 of the
essential oil and the other compound when are used in combination.
An FIC index less than or equal to 0.5 indicates synergy and an index
greater than four indicates antagonism. When the FIC index is greater
than 0.5 and less than four, indicates indifference14.
Finally, an isobologram analysis was performed to demonstrate
the synergic effect among drugs (A and B). The concentrations of drugs
A and B required to produce a defined single-agent effect (EC50), when
used as single agents, are placed on the x and y axes in a two-coordinate
plot, corresponding to (CA, 0) and (0, CB), respectively. The line
connecting these two points is the line of additive. Them, the
concentrations of the two drugs used in combination to provide the
same effect, denoted as (cA, cB), are placed in the same plot. Synergy,
additive, or antagonism are indicated when (cA, cB) is located below,
on, or above the line, respectively26.
The essential oil had a MIC and EC50 values of 27.82 and 3.74 µg/
mL, respectively. The effect on the in vitro growth of L. amazonensis,
caused by each compound used in this study in an individual manner,
and the results obtained when promastigotes were treated with different
combinations is showed in Table 1. The meglumine antimoniate was
inactive, which have been reported in the literature17. We observed
synergy between the essential oil and pentamidine, with a FICI value
less than 0.5, which indicated that the synergism has biological
relevance14. This result was demonstrated through isobologram analyses
(Fig. 1). An indifferent effect was appreciated when the essential oil
incubated together with meglumine antimoniate or amphotericin B on
promastigotes.
Several works have shown that some drugs increased their
antileishmanial effect in conjunction with new antileishmanial agents.
For example: (i) a combination of paromomycin plus antimony over
60 days cured the diffuse cutaneous leishmaniasis due to L. aethiopica22;
(ii) clinical trials of allopurinol in combination with pentamidine for
visceral leishmaniasis shown better results when used in a combination9;
(iii) imiquimod, an immunomodulator, was more efficient when the
Table 1
Activity of each compound studied against promastigotes of L. amazonensis and the results of the combination among studied compounds expressed as FIC index
Compound MICa ± SDb (µg/mL) EC50c ± SD (µg/mL) FIC Indexd Interactione
Meglumine antimoniate - - 1.790 Indifference
Amphotericin B 0.160 ± 0.002 0.030 ± 0.003 1.622 Indifference
Pentamidine 3.100 ± 0.010 0.370 ± 0.010 0.453 Synergism
a: MIC - lowest concentration that caused 100% of inhibition of the parasite growth. b: SD - standard deviation. c: EC50 - concentration that caused 50% of inhibition of
the parasite growth. d: FIC Index: [A]/EC50A + [B]/EC50B, where EC50A and EC50B are the EC50 of each compound alone and [A] and [B] are the EC50 of the essential
oil and the other compound when are used in combination. The EC50 for each compound alone are given in Table 1. e: Interaction effect combined with the essential oil;
Terminology for describing results of combination testing. -: Inactive
Fig. 1 - Result of isobolograms analysis between the essential oil from Chenopodium
ambrosioides and pentamidine. The line indicates synergy, additivity, or antagonism when
the point (cA, cB) is located below, on, or above the line, respectively. The point (cA, cB) is the
result of plotting the EC50 obtained to essential oil and pentamidine when the drugs are used
in combination.
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ointment was used in conjunction with antimonials in patients with
cutaneous leishmaniasis3; (iiii) Different interactions were found in
vivo, where the highest potentiation of miltefosine activity was achieved
with amphotericin B19.
Synergism among antileishmanial agents might occur in one of
several ways. The inhibition of different stages of the same biochemical
pathway represents one type of mechanisms of synergism14. It is possible
that this mechanism explain the synergistic effect found between
pentamidine and the essential oil. Multiple mechanism of action had
been proposed for pentamidine in kinetoplastid parasites, including DNA
binding4,6. On the other hand, the exact mechanism of action of the
essential oil is not known, but some authors hypothesized that ascaridole
(endoperoxide), an active molecule, generates free radicals which can
act on parasitic DNA10,25. Although we are thinking in a correlation
between DNA binding affinity and synergism found, this may not be the
only factor contributing to increase of the antileishmanial activity.
DNA molecules in Leishmania are in a prominent centrally
positioned nucleus23. The parasite genome is spread over 36
chromosomes and it can be estimated that contains up to 9800 genes13,18.
Additionally, a single branched mitochondrion is present which may
extend the whole length of the cell with a large DNA content, termed
kinetoplast23. Both DNA pools are implicated in the development of
biological phenotype and different processes in Leishmania parasite1,23.
On the other hand, the essential oil and pentamidine may have different
preferences for specific DNA sequences. It could indicate that particular
genes or DNA segments may be damaged, which could be related with
the high activity observed.
The pentamidine is one of drugs for clinical use in leishmaniasis
and it is used in visceral leishmaniasis (cases resistant to antimonial
substances) and in cutaneous, diffuse-cutaneous and mucocutaneous
leishmaniasis4. In Colombia, the efficacy of the drug was demonstrated
after repeated administration of 2 mg/kg every other day for seven
days. This regimen was 96% effective in patients infected with L.
panamensis21. However, ANDERSEN et al.2 reported a low cure rate
for pentamidine (35%) in patients infected with L. braziliensis in Peru.
Generally, for cutaneous leishmaniasis, the cure rate associated with
low dose of pentamidine given for a short period makes it an attractive
alternative to antimonies and the treatment of choice in cases as well
as antimonies treatment failure cases20.
The comparison of results across in vivo studies requires careful
consideration of the nature of the pathogen, host, host immune status,
study design and study endpoints14. However, an approach to analysis
of intracellular amastigotes and/or in vivo investigations of
combinations between the essential oil and pentamidine is specially
recommended.
RESUMO
Efeito combinado do óleo de essência de Chenopodium
ambrosioides e drogas anti-leishmaniose nos promastigotas de
Leishmania amazonensis
Até hoje não temos vacina contra a Leishmania e a quimioterapia
é a indicação para o controle desta doença. Os remédios que hoje
utilizamos são tóxicos e muito caros e além disso o resultado não é
sempre o desejado. Por isso, uma terapia de combinação é a melhor
opção. Este trabalho mostra que o óleo de essência de C. ambrosioides
tem atividade sinérgica junto com a pentamidina sobre os promastigotas
de L. amazonensis, diferente do resultado da combinação de antimônio
de meglumine e anfotericina B e o óleo de essência.
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